Secarna Pharmaceuticals, a biopharmaceutical company, has signed an agreement with Scenic Biotech B.V., a pioneer in modifier therapies for severe genetic diseases, covering the discovery and co-development of oligonucleotides against a novel target identified and validated by Scenic Biotech’s proprietary Cell-Seq platform. Secarna will lead the oligonucleotide discovery part of the collaboration, bringing OligoCreator, its proprietary AI-empowered oligonucleotide discovery and development pl...